EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseVergleichsstudieOpen Access · CC BY 4.0

Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials

Sultan Hamarsheh iD, Abdel Rahman Jaber, Omar Abu-Khazneh, Celina R Andonie iD, Saleem Majadleh, Anwar Zahran iD, Hazem Ayesh iD

Endocrinology, Diabetes & Metabolism · 2026

DOI: 10.1002/edm2.70248 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2026. Verfasst von Sultan Hamarsheh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, An-Najah National University, Nablus, Palestine. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptides, Overweight, Anti-Obesity Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk. Tirzepatide, semaglutide, cagrilintide and their combination (CagriSema) have demonstrated efficacy in clinical trials; however, no direct head‐to‐head studies have compared all advanced anti‐obesity medications. This network meta‐analysis examines their comparative efficacy and safety.

Methods

We systematically searched PubMed, Scopus and Cochrane Central for randomized controlled trials comparing these medications with placebo in adults with overweight or obesity. Outcomes included changes in percent body weight, absolute weight, waist circumference, BMI, patients achieving ≥ 5% to ≥ 20% weight loss, HDL‐C and safety outcomes (AEs, serious AEs, gastrointestinal AEs and treatment discontinuation). Random‐effects model and network meta‐analysis methods were employed.

Results

Twenty‐five trials involving 12 interventions met the inclusion criteria. Tirzepatide 15 mg resulted in the greatest percent weight reduction (MD −17.97%), followed by CagriSema (MD −17.84%) and semaglutide 7.2 mg (MD −14.66%). At the ≥ 20% weight‐loss threshold, CagriSema demonstrated marked superiority (RR 27.82), followed by tirzepatide 15 mg (RR 23.70). Gastrointestinal adverse events increased with all treatments (RR 1.33–1.91), and treatment discontinuation was highest with semaglutide 7.2 mg (RR 3.09). Serious adverse events remained comparable to placebo across all regimens.

Conclusion

Tirzepatide 15 mg and CagriSema achieve the greatest weight reduction, including ≥ 20% body weight loss. Gastrointestinal adverse events rise with treatment intensity, while serious adverse events remain comparable to placebo. These findings support dual‐pathway and combination incretin therapies as preferred options for patients requiring substantial weight loss. Treatment selection should be individualized based on comorbidity burden, tolerability and weight loss goals, recognizing that ≥ 5% weight loss improves metabolic parameters while ≥ 10% is needed for meaningful comorbidity reduction. Future head‐to‐head trials are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGlucagon-Like PeptidesOverweightAnti-Obesity AgentsGlucagon-Like Peptide 1HumansTirzepatideSemaglutideRandomized Controlled Trials as TopicWeight LossTreatment OutcomeGastric Inhibitory Polypeptide

Substanzen

TirzepatideSemaglutideGlucagon-Like PeptidesAnti-Obesity AgentsGlucagon-Like Peptide 1Gastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Department of Medicine, An-Najah National University, Nablus, Palestine.
  • School of Medicine, University of Jordan, Amman, Jordan.
  • Al-Quds University, Jerusalem, Palestine.
  • Deaconess Health System, Evansville, Indiana, USA.
  • Adjunct Clinical Assistant Professor of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Sultan Hamarsheh, Celina R Andonie, Anwar Zahran, Hazem Ayesh

Zitieren

APA

Hamarsheh, S., Jaber, A. R., Abu-Khazneh, O., Andonie, C. R., Majadleh, S., Zahran, A., & Ayesh, H. (2026). Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70248

Vancouver

Hamarsheh S, Jaber AR, Abu-Khazneh O, Andonie CR, Majadleh S, Zahran A, et al. Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials. Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70248

BibTeX
@article{Hamarsheh2026,
  author = {Hamarsheh, Sultan and Jaber, Abdel Rahman and Abu-Khazneh, Omar and Andonie, Celina R and Majadleh, Saleem and Zahran, Anwar and Ayesh, Hazem},
  title = {Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  doi = {10.1002/edm2.70248}
}
Kostenlos starten →